Shares of INmune Bio Inc (NASDAQ:INMB) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price target of $13.00 for the company, according to Zacks. Zacks has also given INmune Bio an industry rank of 60 out of 255 based on the ratings given to its competitors.
Separately, Maxim Group assumed coverage on INmune Bio in a research report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 target price for the company.
NASDAQ:INMB opened at $10.20 on Tuesday. INmune Bio has a 1-year low of $7.00 and a 1-year high of $10.95.
INmune Bio Company Profile
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
See Also: What causes a recession?
Get a free copy of the Zacks research report on INmune Bio (INMB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.